MedTrace Logo

Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.

NCT01233739 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2013-02-22

No results posted yet for this study

Summary

Patients who present rhizarthrosis diagnostic will be randomized to be treated with chondroitin sulfate or placebo during 24 weeks to study the effect of the treatment with objective and subjective indicators of pain and sensibility.

Conditions

  • Rhizarthrosis

Interventions

DRUG

Chondroitin sulfate

Administration of 2 capsules of 400 mg of chondroitin sulfate orally.

DRUG

Placebo

Administration of 2 capsules of placebo orally.

Sponsors & Collaborators

  • Juan A. Arnaiz

    lead OTHER

Principal Investigators

  • Joaquím Forés, MD · Hospital Clínic i Provincial de Barcelona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233739 on ClinicalTrials.gov